CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 133 enrolled
Drug / intervention
BOS-589 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03977155
NCT03977155Phase 2Completed
CompareCT.gov

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Boston Pharmaceuticals·interventional·Posted Jun 6, 2019·Updated Jun 7, 2021

In Brief

A Phase 2 clinical trial evaluating BOS-589 and Placebo for Diarrhea-predominant Irritable Bowel Syndrome. Completed, enrolled 133 participants across 58 sites.

Detailed Summary

This study is being conducted to evaluate in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) the abdominal pain response to BOS-589 after 4 weeks of treatment and to evaluate the overall safety and tolerability of BOS-589 in the treatment of IBS-D during 4 weeks of treatment, relative to placebo (PBO).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiarrhea-predominant Irritable Bowel Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 6, 2019
Enrollment StartJun 4, 2019
Primary CompletionMay 6, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.1 years ago

Interventions

BOS-589drug

oral tablets

Placebodrug

oral tablets